Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2] (Ab89901)
Wilms tumor protein, WT33, WT1
详细信息
特异性
Expression levels of the target protein vary with sample type and some optimisation may be required.
背景信息
Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2] (ab89901) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-P and WB. Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2] (ab89901) was first used in a scientific publication in 2011 and has been cited over 252 times in peer reviewed journals. It's performance in IHC in mouse and human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2] (ab89901) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2] (ab89901) has 40 independent reviews from customers. Anti-Wilms Tumor Protein antibody [CAN-R9(IHC)-56-2] (ab89901) specifically detects Wilms Tumor Protein (UniProt ID: P19544; Molecular weight: 50kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone CAN-R9(IHC)-56-2 - ab216646. Antibody clone CAN-R9(IHC)-56-2 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, FITC, Alexa Fluor ® 555 ( ab202635, ab202639, ab223934, ab314587 ). Wilms Tumor Protein (WT1) is a tumor-associated antigen that is overexpressed in various cancers, making it a target for immunotherapeutic approaches. It plays a role in tumor progression and immune evasion, influencing the tumor microenvironment and the effectiveness of immune responses. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.
文献引用 (304)
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10
中性粒细胞胞外陷阱通过扩增表达IL-10的固有样B细胞,促进大网膜中转移前微环境的形成。
Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation.
衰老和携带 BRCA 突变的基质细胞驱动上皮细胞转化
Expression of ENL YEATS domain tumor mutations in nephrogenic or stromal lineage impairs kidney development.
ENL YEATS 结构域肿瘤突变在肾源性或间质谱系中的表达会损害肾脏发育
Axial nephron fate switching demonstrates a plastic system tunable on demand.
轴向肾单位命运转换表明,这是一个可按需调节的可塑性系统
Controlling nephron precursor differentiation to generate proximal-biased kidney organoids with emerging maturity.
控制肾单位前体分化,生成具有逐渐成熟的近端偏向肾脏类器官
Generation of mature epicardium derived from human-induced pluripotent stem cells via inhibition of mTOR signaling
通过抑制mTOR信号通路,利用人诱导多能干细胞生成成熟的心外膜
Podocyte RIPK3 Deletion Improves Diabetic Kidney Disease by Attenuating NF-κB p65 Driven Inflammation.
足细胞 RIPK3 缺失通过减弱 NF-κB p65 驱动的炎症来改善糖尿病肾病
LRRC4 Deficiency Drives Premature Ovarian Insufficiency by Disrupting Metabolic Homeostasis in Granulosa Cells.
LRRC4 缺乏通过破坏颗粒细胞的代谢稳态导致卵巢早衰
TRPC6-targeted dexamethasone nanobubbles with ultrasound-guided theranostics for adriamycin-induced nephropathy.
靶向 TRPC6 的地塞米松纳米泡与超声引导治疗诊断技术在阿霉素诱发肾病中的应用
NAT10 mediates TLR2 to promote podocyte senescence in adriamycin-induced nephropathy.
NAT10 介导 TLR2 促进阿霉素诱导肾病中的足细胞衰老
- 1
- 2
- 3
- 4
- 5
- 6
- 31